Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-18
- Report ID: 3885
- Pages: 310
-
Format:
The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.
Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
Viral vector
o Retroviruses
o Lentiviruses
o Adenoviruses
o Adeno Associated Virus
o Herpes Simplex Virus
o Poxvirus
o Vaccinia Virus
o Others
Non-viral vector
o Naked/Plasmid Vectors
o Gene Gun
o Electroporation
o Lipofection
o Others
By Gene Type
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others
By Application
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious disease
Other Diseases
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
KEY PLAYERS PROFILED
Adaptimmune Therapeutics Plc.
Anchiano Therapeutics Ltd.
Achieve Life Sciences, Inc.
Adverum Biotechnologies, Inc.
Abeona Therapeutics Inc.
Applied Genetic Technologies Corporation
Arbutus Biopharma Corporation,
Audentes Therapeutics, Inc.
AveXis, Inc.
Bluebird Bio, Inc.
Celgene Corporation
CRISPR Therapeutics AG
Editas Medicine, Inc.
Editas Medicine, Inc.
GlaxoSmithKline Plc.
Intellia Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
REGENXBIO Inc.
Spark Therapeutics, Inc.
Sangamo Therapeutics, Inc.
Uniqure N. V.
Voyager Therapeutics, Inc
The other players of the gene therapy market include (companies not profiled in the report):
Amgen
Epeius Biotechnologies
Sanofi
Juno Therapeutics
Advantagene
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Top Player Positioning, 2018
3.4. PorterS Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
3.5.1.2. Increase In Prevalence of Cancer
3.5.1.3. Growth In Awareness Regarding Gene Therapy
3.5.2. Restraints
3.5.2.1. High Cost Associated With Gene Therapies
3.5.2.2. Unwanted Immune Responses
3.5.3. Opportunities
3.5.3.1. Untapped Potential For Emerging Markets
Chapter 4: Gene Therapy Market, By Vector Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Viral Vectors
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Size And Forecast, By Type
4.2.4. Market Size And Forecast, By Country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-Associated Virus
4.2.9. Herpes Simplex Virus
4.2.10. Poxvirus
4.2.11. Vaccinia Virus
4.2.12. Others
4.3. Non-Viral Techniques
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Size And Forecast, By Type
4.3.4. Market Size And Forecast, By Country
4.3.5. Naked Plasmid Vector
4.3.6. Gene Gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others
Chapter 5: Gene Therapy Market, By Gene Type
5.1. Overview
5.1.1. Market Size And Forecast, Type
5.2. Antigen
5.2.1. Market Size And Forecast
5.2.2. Market Size And Forecast, By Country
5.3. Cytokine
5.3.1. Market Size And Forecast
5.3.2. Market Size And Forecast, By Country
5.4. Tumor Suppressor
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Size And Forecast, By Country
5.5. Suicide Gene
5.5.1. Market Size And Forecast
5.5.2. Market Size And Forecast, By Country
5.6. Deficiency
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Size And Forecast, By Country
5.7. Growth Factors
5.7.1. Market Size And Forecast, By Region
5.7.2. Market Size And Forecast, By Country
5.8. Receptors
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Size And Forecast, By Country
5.9. Others
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Size And Forecast, By Country
Chapter 6: Gene Therapy Market, By Application
6.1. Overview
6.1.1. Market Size And Forecast, By Application
6.2. Oncological Disorders
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Size And Forecast, By Country
6.3. Rare Diseases
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Size And Forecast, By Country
6.4. Cardiovascular Diseases
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Size And Forecast, By Country
6.5. Neurological Disorders
6.5.1. Market Size And Forecast
6.5.2. Market Size And Forecast, By Country
6.6. Infectious Diseases
6.6.1. Market Size And Forecast, By Region
6.6.2. Market Size And Forecast, By Country
6.7. Other Diseases
6.7.1. Market Size And Forecast
6.7.2. Market Size And Forecast, By Country
Chapter 7: Gene Therapy Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Vector Type
7.2.4. Market Size And Forecast, By Gene Type
7.2.5. Market Size And Forecast, By Application
7.2.5.1. U.S. Market Size And Forecast, By Vector Type
7.2.5.2. U.S. Market Size And Forecast, By Gene Type
7.2.5.3. U.S. Market Size And Forecast, By Application
7.2.5.4. Canada Market Size And Forecast, By Vector Type
7.2.5.5. Canada Market Size And Forecast, By Gene Type
7.2.5.6. Canada Market Size And Forecast, By Application
7.2.5.7. Mexico Market Size And Forecast, By Vector Type
7.2.5.8. Mexico Market Size And Forecast, By Gene Type
7.2.5.9. Mexico Market Size And Forecast, By Application
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Vector Type
7.3.4. Market Size And Forecast, By Gene Type
7.3.5. Market Size And Forecast, By Application
7.3.5.1. Germany Market Size And Forecast, By Vector Type
7.3.5.2. Germany Market Size And Forecast, By Gene Type
7.3.5.3. Germany Market Size And Forecast, By Application
7.3.5.4. France Market Size And Forecast, By Vector Type
7.3.5.5. France Market Size And Forecast, By Gene Type
7.3.5.6. France Market Size And Forecast, By Application
7.3.5.7. Uk Market Size And Forecast, By Vector Type
7.3.5.8. Uk Market Size And Forecast, By Gene Type
7.3.5.9. Uk Market Size And Forecast, By Application
7.3.5.10. Italy Market Size And Forecast, By Vector Type
7.3.5.11. Italy Market Size And Forecast, By Gene Type
7.3.5.12. Italy Market Size And Forecast, By Application
7.3.5.13. Spain Market Size And Forecast, By Vector Type
7.3.5.14. Spain Market Size And Forecast, By Gene Type
7.3.5.15. Spain Market Size And Forecast, By Application
7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
7.3.5.18. Rest of Europe Market Size And Forecast, By Application
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Vector Type
7.4.4. Market Size And Forecast, By Gene Type
7.4.5. Market Size And Forecast, By Application
7.4.5.1. Japan Market Size And Forecast, By Vector Type
7.4.5.2. Japan Market Size And Forecast, By Gene Type
7.4.5.3. Japan Market Size And Forecast, By Application
7.4.5.4. China Market Size And Forecast, By Vector Type
7.4.5.5. China Market Size And Forecast, By Gene Type
7.4.5.6. China Market Size And Forecast, By Application
7.4.5.7. India Market Size And Forecast, By Vector Type
7.4.5.8. India Market Size And Forecast, By Gene Type
7.4.5.9. India Market Size And Forecast, By Application
7.4.5.10. South Korea Market Size And Forecast, By Vector Type
7.4.5.11. South Korea Market Size And Forecast, By Gene Type
7.4.5.12. South Korea Market Size And Forecast, By Application
7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application
7.5. Lamea
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Vector Type
7.5.4. Market Size And Forecast, By Gene Type
7.5.5. Market Size And Forecast, By Application
7.5.5.1. Brazil Market Size And Forecast, By Vector Type
7.5.5.2. Brazil Market Size And Forecast, By Gene Type
7.5.5.3. Brazil Market Size And Forecast, By Application
7.5.5.4. South Africa Market Size And Forecast, By Vector Type
7.5.5.5. South Africa Market Size And Forecast, By Gene Type
7.5.5.6. South Africa Market Size And Forecast, By Application
7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type
7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type
7.5.5.9. Rest of Lamea Market Size And Forecast, By Application
Chapter 8: Company Profile
8.1. Adaptimmune Therapeutics Plc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Anchiano Therapeutics Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Achieve Life Sciences, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Key Strategic Moves And Developments
8.4. Adverum Biotechnologies, Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves And Developments
8.5. Abeona Therapeutics Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Applied Genetic Technologies Corporation
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Arbutus Biopharma Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments
8.8. Audentes Therapeutics Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.8.4. Key Strategic Moves And Developments
8.9. Avexis Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Key Strategic Moves And Developments
8.10. Bluebird Bio, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
8.11. Celgene Corporation
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
8.11.6. Key Strategic Moves And Developments
8.12. Crispr Therapeutics Ag
8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Product Portfolio
8.12.4. Business Performance
8.12.5. Key Strategic Moves And Developments
8.13. Editas Medicine, Inc.
8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Operating Business Segments
8.13.4. Product Portfolio
8.13.5. Business Performance
8.13.6. Key Strategic Moves And Developments
8.14. Gilead Sciences, Inc.
8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Operating Business Segments
8.14.4. Product Portfolio
8.14.5. Business Performance
8.14.6. Key Strategic Moves And Developments
8.15. Glaxosmithkline Plc
8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Operating Business Segments
8.15.4. Product Portfolio
8.15.5. Business Performance
8.15.6. Key Strategic Moves And Developments
8.16. Intellia Therapeutics Inc.
8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Operating Business Segments
8.16.4. Product Portfolio
8.16.5. Business Performance
8.16.6. Key Strategic Moves And Developments
8.17. Merck & Co., Inc.
8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Operating Business Segments
8.17.4. Product Portfolio
8.17.5. Business Performance
8.17.6. Key Strategic Moves And Developments
8.18. Novartis Ag
8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Operating Business Segments
8.18.4. Product Portfolio
8.18.5. Business Performance
8.18.6. Key Strategic Moves And Developments
8.19. Regenxbio, Inc.
8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Product Portfolio
8.19.4. Business Performance
8.19.5. Key Strategic Moves And Developments
8.20. Spark Therapeutics, Inc.
8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Operating Business Segments
8.20.4. Product Portfolio
8.20.5. Business Performance
8.20.6. Key Strategic Moves And Developments
8.21. Sangamo Therapeutics, Inc.
8.21.1. Company Overview
8.21.2. Company Snapshot
8.21.3. Operating Business Segments
8.21.4. Product Portfolio
8.21.5. Business Performance
8.21.6. Key Strategic Moves And Developments
8.22. Uniqure N. V.
8.22.1. Company Overview
8.22.2. Company Snapshot
8.22.3. Operation Segments
8.22.4. Product Portfolio
8.22.5. Business Performance
8.22.6. Key Strategic Moves And Developments
8.23. Voyager Therapeutics, Inc.
8.23.1. Company Overview
8.23.2. Company Snapshot
8.23.3. Operating Business Segments
8.23.4. Product Portfolio
8.23.5. Business Performance
8.23.6. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
